HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Scope & Guideline

Exploring Innovations in Blood Disorders and Cancer Care

Introduction

Welcome to the HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0889-8588
PublisherW B SAUNDERS CO-ELSEVIER INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1987 to 2024
AbbreviationHEMATOL ONCOL CLIN N / Hematol. Oncol. Clin. North Am.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899

Aims and Scopes

The journal 'Hematology-Oncology Clinics of North America' aims to provide a comprehensive platform for the latest advancements in hematology and oncology, focusing on the clinical aspects of cancer care and treatment. It encompasses a diverse range of topics that reflect the complexities of cancer treatment and research, with a strong emphasis on multidisciplinary approaches to patient management.
  1. Clinical Innovations in Cancer Treatment:
    The journal features papers on the latest advancements in cancer therapies, including immunotherapy, targeted therapies, and novel drug developments, demonstrating a commitment to improving patient outcomes.
  2. Research on Cancer Pathophysiology:
    It explores the biological mechanisms underlying various cancers, including genetic and molecular studies that inform treatment strategies and improve understanding of disease progression.
  3. Multidisciplinary Management of Cancer:
    The journal emphasizes the importance of collaboration among various specialties in the management of cancer, showcasing studies on surgical, medical, and supportive care approaches.
  4. Health Disparities in Cancer Care:
    There is a focus on addressing inequities in cancer treatment and outcomes, with research highlighting disparities based on socioeconomic status, geography, and access to care.
  5. Preventive Oncology and Early Detection:
    The journal promotes research on cancer prevention strategies, screening methods, and the identification of precursor lesions to facilitate early diagnosis and intervention.
The journal has adapted to the rapidly changing landscape of cancer research and treatment, with several emerging themes gaining traction in recent publications. This section outlines these trending areas that are likely to shape future research and clinical practice.
  1. Advancements in Immunotherapy:
    Recent publications increasingly focus on immunotherapy, particularly CAR T-cell therapy and checkpoint inhibitors, underscoring the shift towards harnessing the immune system to combat cancer.
  2. Targeted Therapies and Precision Medicine:
    There is a prominent trend towards the exploration of targeted therapies tailored to individual genetic profiles, reflecting a growing commitment to precision medicine in oncology.
  3. Biomarkers for Early Detection and Treatment Response:
    Emerging research on biomarkers for cancer detection and monitoring treatment responses is gaining importance, highlighting the need for tools that can guide clinical decision-making.
  4. Global Health and Cancer Disparities:
    The journal is increasingly addressing global health issues in oncology, focusing on disparities in cancer care and treatment outcomes, particularly in low- and middle-income countries.
  5. Integration of Technology in Cancer Care:
    Innovations in technology, such as telemedicine and digital health, are becoming more prevalent in the journal, reflecting the adaptation of cancer care delivery in an evolving healthcare landscape.

Declining or Waning

As the field of oncology evolves, certain themes within 'Hematology-Oncology Clinics of North America' appear to be diminishing in frequency or focus. This section highlights these waning areas, reflecting shifts in research priorities and clinical practice.
  1. Traditional Chemotherapy Approaches:
    With the rise of targeted therapies and immunotherapies, traditional chemotherapy regimens are receiving less emphasis in recent publications, indicating a shift towards more personalized treatment strategies.
  2. Basic Science Research Without Clinical Application:
    There is a noticeable decline in purely basic science research that lacks direct clinical relevance, as the journal increasingly prioritizes studies that translate findings into practical applications in patient care.
  3. Focus on Established Cancer Types:
    Research on well-established cancer types, such as breast and prostate cancer, is becoming less prominent as newer, less common malignancies gain attention, reflecting a broadening scope of interest within the oncology community.

Similar Journals

Gaceta Mexicana de Oncologia

Innovative Findings, Accessible Solutions in Oncology.
Publisher: SOC MEXICANA ONCOLOGIA, A CISSN: 1665-9201Frequency: 6 issues/year

Gaceta Mexicana de Oncologia, published by the SOC MEXICANA ONCOLOGIA, A C, is a prominent Open Access journal that has contributed significantly to the field of oncology since its inception in 2002. With an ISSN of 1665-9201, this journal is dedicated to disseminating high-quality research pertaining to cancer studies, making it an essential resource for researchers, healthcare professionals, and students alike. Operating out of Spain, it serves as a platform for sharing innovative findings and clinical advancements in oncology. The journal's impact in the research community is reflected in its current rankings, placing it in the Q4 category for Cancer Research and Oncology fields. Despite its emerging status within the academic tiers, Gaceta Mexicana de Oncologia aims to enhance its presence in the scholarly domain, especially during its converged years from 2009 to 2024. The accessibility of its articles empowers a wider audience, fostering collaboration and knowledge-sharing necessary for combating cancer in diverse populations.

LANCET ONCOLOGY

Pioneering insights in the fight against cancer.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Translational Oncology

Connecting Science and Clinical Practice in Cancer Care
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

South Asian Journal of Cancer

Fostering innovation in South Asian cancer research.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Frontiers in Oncology

Leading the charge in transformative oncology research.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

ONCOLOGY REPORTS

Connecting Knowledge and Innovation in Cancer Care
Publisher: SPANDIDOS PUBL LTDISSN: 1021-335XFrequency: 12 issues/year

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

BRITISH JOURNAL OF CANCER

Connecting Researchers and Clinicians in the Fight Against Cancer.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Cancers

Unleashing insights to combat cancer effectively.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

World Journal of Clinical Oncology

Transforming Patient Care through Groundbreaking Research
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Illuminating the path to better cancer and blood disorder management.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.